Overview

Phase 3 Open-Label Extension Study of TD-9855 for Treating Symptomatic nOH in Subjects With Primary Autonomic Failure

Status:
Active, not recruiting
Trial end date:
2025-12-01
Target enrollment:
Participant gender:
Summary
A Phase 3, multi-center, open-label study to evaluate the safety and tolerability of ampreloxetine in subjects with primary autonomic failures (MSA, PD, and PAF) and symptomatic nOH over 182 weeks.
Phase:
Phase 3
Details
Lead Sponsor:
Theravance Biopharma